Pill cameras could spot rare gut cancers in lynch syndrome patients
NCT ID NCT05704010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether a swallowed video capsule (a pill-sized camera) can help find small bowel cancer early in people with Lynch syndrome, a genetic condition that raises cancer risk. About 100 participants will swallow a capsule every two years to take pictures of their small intestine. The goal is to measure how often pre-cancerous growths or cancers appear, which could guide future screening recommendations.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Video capsule endoscopy (a pill-sized camera swallowed to take pictures of the small intestine)
- What this could lead to
- If successful, this study could show that regular video capsule endoscopy helps detect small bowel cancer early in people with Lynch syndrome, potentially improving outcomes.
- What could go wrong
- This is an observational registry, not a treatment trial. It will not test whether screening actually saves lives, and the capsule may miss some lesions. Results will take years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2018
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathogenic germline variant in one of the MMR genes (MLH1, MSH2/Epcam, MSH6, or PMS2). Exclusion Criteria: * Patients younger than 18 years of age * Patients unwilling or unable to provide informed consent * Patients with prior small bowel surgery * Patients with a contraindication to VCE
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lynch syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
San Raffaele Scientific Institute, Gastroenterology and Gastrointestinal Endoscopy Unit
RECRUITINGMilan, Lombardy, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Direct-to-Abdomen chemotherapy tame GI cancers that spread?
- A watchful eye: could alternating scans outsmart pancreatic cancer?
- Can a walking routine alter cancer biomarkers? new trial investigates
- Digital assistant aims to close gaps in hereditary cancer care
- Lynch syndrome patients share colonoscopy struggles in new survey
- Personalized vaccine aims to stop lynch syndrome cancers before they start